Experienced in Giant Papillary Conjunctivitis

Gabriella Galffy

70 Munkácsy Mihály Street, 
Toeroekbalint, PE, HU 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Giant Papillary Conjunctivitis
70 Munkácsy Mihály Street, 
Toeroekbalint, PE, HU 
OverviewLocationsClinical Research

Overview

Gabriella Galffy practices in Toeroekbalint, Hungary. Ms. Galffy is rated as an Experienced expert by MediFind in the treatment of Giant Papillary Conjunctivitis. Her top areas of expertise are Allergic Rhinitis, Lung Cancer, Small Cell Lung Cancer (SCLC), and Chronic Obstructive Pulmonary Disease (COPD).

Her clinical research consists of co-authoring 91 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Giant Papillary Conjunctivitis.

Gender
Female

Locations

70 Munkácsy Mihály Street, Toeroekbalint, PE 2045, Hungary
Other Locations
58 Tűzoltó Street, Budapest, BU 1085, Hungary

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, HD204, Carboplatin, Paclitaxel
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
View 4 Less Clinical Trials

91 Total Publications

Human Leukocyte Antigen-DR Expression on Monocytes Is a Useful Predictor in a Systemic Inflammation Response-Based Prognostic Model in Advanced Non-Small Cell Lung Cancer.
Human Leukocyte Antigen-DR Expression on Monocytes Is a Useful Predictor in a Systemic Inflammation Response-Based Prognostic Model in Advanced Non-Small Cell Lung Cancer.
Journal: International journal of molecular sciences
Published: August 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Galffy's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile